Abstract: The disclosure relates generally to alpha polyglutamated pemetrexed, formulations containing liposomes filled with alpha polyglutamated pemetrexed, methods of making the alpha polyglutamated pemetrexed and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated pemetrexed and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).
Abstract: The present invention relates to a solution for resisting destruction of living plants and a related method. A solution including a buffered amine oxide admixed with at least one material selected from the group consisting of insecticides and fungicides is applied to the living plant and provides a synergistically effective greater resistance to living plant deterioration than any of the individual buffered amine oxide, insecticides and fungicides achieve. A related method is disclosed.
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
October 10, 2023
Assignee:
KOP-COAT, INC.
Inventors:
Ronald W. Clawson, Jr., Hans A. Ward, Kenneth A. Cutler, Cameron R. Scott
Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R1-R6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
October 10, 2023
Assignee:
REGENTS OF THE UNIVERSITY OF MINNESOTA
Inventors:
Ingrid Gunda Georg, Narsihmulu Cheryala
Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGF?2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGF?2-associated diseases, disorders and/or conditions.
Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
Type:
Grant
Filed:
March 25, 2021
Date of Patent:
September 19, 2023
Assignee:
Exelixis, Inc.
Inventors:
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Abstract: The present technology relates to a method for treating anxiety or an anxiety-related disorder in an animal subject, the method comprising administering an effective amount of cannabidiol (CBD) to the animal subject.
Abstract: Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.
Type:
Grant
Filed:
September 28, 2021
Date of Patent:
September 5, 2023
Assignees:
CREIGHTON UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (TENNESSEE NOT FOR PROFIT CORPORATION)
Inventors:
Jian Zuo, Santanu Hati, Marisa Laura Zallocchi, Robert Hazlitt, Jaeki Min
Abstract: In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 preconditioned stem cells is obtained by exposing stem cells to LDR. Uses of the preconditioned stem cells are also provided. In other aspects, the stem cells are muscle stem cells.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
August 29, 2023
Assignee:
ATOMIC ENERGY OF CANADA LIMITED/ENERGIE ATOMIQUE DU CANADA LIMITÈE
Inventors:
Dmitry Klokov, Soji Sebastian, Yevgeniya Le
Abstract: The present disclosure provides processes for preparing a crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile and related intermediate compounds.
Type:
Grant
Filed:
October 7, 2021
Date of Patent:
August 29, 2023
Assignee:
Theravance Biopharma R&D LP, LLC
Inventors:
Norbert Kraut, Matteo Conza, Anja Huste, Vit Lellek, Bjorn Gielen, Christian Pater, Dimitar Filipov, Xiaojun Huang, Stephen Roseblade
Abstract: Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
August 29, 2023
Assignee:
SRI International
Inventors:
Kathlynn C. Brown, Curtis Allred, Michael McGuire
Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3 -(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
Type:
Grant
Filed:
October 20, 2021
Date of Patent:
August 29, 2023
Assignee:
KalVista Pharmaceuticals Limited
Inventors:
Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards
Abstract: The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or neoplastic disease, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, retinoblastoma, or multiple endocrine neoplasia type 1.
Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
Type:
Grant
Filed:
October 29, 2020
Date of Patent:
August 15, 2023
Inventors:
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
Type:
Grant
Filed:
February 4, 2021
Date of Patent:
August 15, 2023
Assignees:
President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.
Type:
Grant
Filed:
February 28, 2019
Date of Patent:
August 15, 2023
Assignee:
Annapurna Bio, Inc.
Inventors:
Haifeng Tang, Sarah Boyce, Michael Hanson, Zhe Nie
Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
August 8, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
Type:
Grant
Filed:
April 7, 2021
Date of Patent:
August 8, 2023
Assignee:
Ardelyx, Inc.
Inventors:
Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell